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Pancreatic b cell failure is central in the pathogenesis of type 2 diabetes (T2D), but the mechanisms involved
remain unclear. Mahdi and colleagues (2012) couple global evaluation of gene expression with coexpression
network analysis of human islets from T2D patients to identify SFRP4 as an early mediator of b cell dysfunc-
tion in T2D.Genome-wide association studies for
T2D have so far identified 65 susceptibility
loci for the disease (Morris et al., 2012),
but together these loci account for less
than 10% of the variance in disease
susceptibility. This contrasts with the situ-
ation in type 1 diabetes (T1D), where such
studies have identified 50 loci across the
human genome associated with T1D that
explain nearly 80% of the heritability
(Pociot et al., 2010). Other approaches
to identify basic mechanisms of disease
are therefore needed (Taneera et al.,
2012). Furthermore, direct studies of the
diseased human tissue—in the case of
T2D, human islets are the gold standard
given the central role of b cell dysfunc-
tion in its pathogenesis—are essential to
further our understanding of human dia-
betes (Cnop et al., 2005; Kahn, 2003). In
this issue of Cell Metabolism, Mahdi and
colleagues tackle these challenges by
performing microarray analyses of human
islets isolated from T2D and normoglyce-
mic individuals (Mahdi et al., 2012) (Fig-
ure 1). They identify a group of T2D-
associated genes related to interleukin-1
(IL-1), a proinflammatory cytokine, andshow that secreted frizzled-related pro-
tein 4 (SFRP4) is highly associated
with T2D.
Previous work already suggested that
IL-1b plays a role in b cell dysfunction
and death in T1D and T2D. However,
whereas a role for inflammation in b cell
loss is well established in the context of
T1D (Eizirik et al., 2009), it has remained
controversial for T2D (Cnop et al., 2005;
Donath et al., 2008). To explain local
IL-1b production in the islets of T2D indi-
viduals, one model proposed that IL-1b
production was induced by glucose,
leading to upregulation of the apoptotic
Fas receptor and ligand and b cell
‘‘suicide’’ (Donath et al., 2008), but this
was not confirmed by other groups (re-
viewed in Cnop et al., 2005). In recent
years a more nuanced view of inflamma-
tion in T2D islets emerged, consisting
of mild upregulation of cytokines and
chemokines in islets from T2D patients,
possibly mediated by increased circu-
lating concentrations of the free fatty
acid palmitate that induces islet IL-1b
and TNF-a expression (Igoillo-Esteve
et al., 2010). Experimental findings showthat this metabolic ‘‘T2D-like’’ stress
induces a mild inflammatory response,
representing around 5%–10% of the pro-
inflammatory response of human islets
exposed to ‘‘T1D-like’’ conditions (Cnop
et al., 2005; Igoillo-Esteve et al., 2010).
The role for this ‘‘low-intensity’’ innate
immunity-mediated inflammation in b cell
dysfunction and death in T2D remains
unclear. For instance, an IL-1 receptor
antagonist blocked palmitate-induced
chemokine expression, but failed to pre-
vent apoptosis (Igoillo-Esteve et al., 2010).
Using gene expression topology with
weighted gene coexpression network
analysis (in which coexpressed genes
are clustered into gene modules based
on their connectivity), Mahdi et al. now
identify a T2D-related gene module en-
riched for IL-1-related genes. Among the
most connected hub genes, the authors
identify SFRP4 as highly associated with
T2D, HbA1c (a measure of average
glucose levels over the past 2 months),
and insulin secretion (Figure 1). Subse-
quent functional studies then show that
the SFRP4 protein is induced by the cyto-
kine IL-1b. Furthermore, the authors showNovember 7, 2012 ª2012 Elsevier Inc. 555
Figure 1. The Research Strategy of Mahdi and Colleagues Leading to the Identification of
SFRP4
Based on bioinformatics analyses of microarray studies of human islets from type 2 diabetic and nondia-
betic organ donors, Mahdi et al. identify SFRP4 as a hub gene in the gene expression module associated
with type 2 diabetes and insulin secretory defects. Functional studies in in vitro and in vivo models then
shed light on the mechanisms by which SFRP4 causes pancreatic b cell dysfunction. Clinical studies in
prospective cohorts identified SFRP4 as a potential biomarker for future development of type 2 diabetes.
T2D, type 2 diabetes; ND, nondiabetic.
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Previewsthat SFRP4 impairs insulin release both
in vitro in mouse and human islets and
in vivo in SFRP4-treated mice. It does
not, however, decrease b cell viability. In
mechanistic studies, the authors show
that SFRP4 inhibits expression of L-type
and P/Q-type Ca2+ channels, possibly
via Wnt signaling, and thereby hampers
Ca2+ influx, consequently reducing insulin
exocytosis. Importantly, serum SFRP4
levels are elevated in T2D individuals
and inversely correlated with the disposi-
tion index (a measure of b cell function).
SFRP4 levels are increased several years
before diabetes diagnosis, a key observa-
tion confirmed in an independent cohort
(Mahdi et al., 2012). As a whole, these
findings suggest that SFRP4 may be
a potential mediator and early biomarker
of b cell dysfunction in T2D.
These results provide a possiblemolec-
ular link between mild islet inflammation
and defective insulin secretion in T2D.
Taken together with previous findings
(Igoillo-Esteve et al., 2010), the observa-
tions suggest that the low-intensity islet
inflammation in T2D may have a more
relevant role for b cell functional impair-
ment than actual b cell death. It is there-
fore conceivable that the loss of b cell556 Cell Metabolism 16, November 7, 2012 ªmass in T2D is a consequence of meta-
bolic stress induced by chronic exposure
to high glucose and saturated free
fatty acids, independently of inflammation
(Cnop et al., 2005).
In his novel The Island of Doctor
Moreau, H.G. Wells provides an interest-
ing description of the scientific method:
‘‘I asked a question, devised some
methods of getting an answer, and got—
a fresh question.’’ Indeed, the finding of
a pathophysiological role for SFRP4 in
T2D raises many questions. SFRP4 is
subject to alternative splicing, and its
expression is regulated by DNA methyla-
tion of the promoter region. A recent study
of the DNA methylation profile of T2D
human islets identified hypomethylation
across more than 200 gene promoters
(Volkmar et al., 2012); whether SFRP4
expression in T2D islets is induced via
this epigenetic modification remains to
be examined. Does the increase in
SFRP4 expression in T2D islets contribute
to the increase in circulating levels of
SFRP4? This is unlikely, given the ubiqui-
tous expression of SFRP4 and the rela-
tively low expression levels in human
islets. Do T2D human islets secrete more
SFRP4 relative to healthy islets, and do2012 Elsevier Inc.the elevated levels of SFRP4 act in an
auto/paracrine manner to inhibit b cell
function? In clonal rat b cells, the inhibitory
effect of IL-1b on insulin secretion was
slightly attenuated following SFRP4
silencing, suggesting that SFRP4 only
partially contributes to this inhibitory
effect. In human islets, however, IL-1b
alone does not inhibit insulin secretion
(reviewed in Cnop et al., 2005). Are there
other cytokines, besides IL-1b, that affect
insulin release in T2D, and is this via
SFRP4 or other mechanisms that remain
to be discovered? Of note, pharmaceu-
tical industry trials with different IL-1
receptor antagonists in T2D have resulted
in only small improvements in glycemic
control, and most have been discon-
tinued. Mahdi et al. suggest crosstalk
between SFRP4 and Wnt signaling, but
additional studies are required to clarify
the underlying gene networks in pancre-
atic b cells. Since SFRP4 plays a role in
differentiation in other cell types and
inhibits proliferation and angiogenesis, it
would be of interest to determine whether
these mechanisms operate in T2D.
In our opinion, the present study
is a beautiful example of the potential
power of hypothesis-generating ‘‘mining’’
studies. If well powered and controlled
(including, in this case, replication in inde-
pendent samples), based on relevant
tissue (i.e., human islets from diseased
individuals), and analyzed by adequate
bioinformatics tools, they can provide
a comprehensive view of complex bio-
logical problems and point to unexpected
pathways to understand disease mecha-
nisms. In other words, these mining
studies may find gold.REFERENCES
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Hypothalamic RIP-expressing neurons regulate energy balance, but the precise neural pathways and
neurotransmitters mediating this effect remain undetermined. Kong et al. (2012) now demonstrate that RIP
neurons regulate energy expenditure and BAT thermogenesis predominantly via a GABAergic arcuate-
paraventricular-hindbrain pathway.The hypothalamus is a critical regulator of
energy balance and glucose homeo-
stasis. Over the past 10–15 years a great
deal of attention has been devoted
to hypothalamic neurons that produce
agouti-related peptide (AgRP) and neu-
rons that express proopiomelanocortin
(POMC) in part because of the importance
of these neuronal populations in the inte-
gration of peripheral blood-born signals,
including endocrine signals and nutrients
(Williams and Elmquist, 2012; Sa´nchez-
Lasheras et al., 2010; Gao and Horvath,
2007). However, the hypothalamus con-
tains a variety of other neuronal systems,
and their relative contributions to the re-
gulation of energy balance remains in-
completely understood. In addition, a
better understanding of the complex
neuronal network that regulates appetite
and body weight is needed. In a recent
issue of Cell, Kong et al. (2012) mapped
the synaptic interactions of a subpopula-
tion of GABAergic neurons from the
arcuate nucleus (ARH) with other hypo-
thalamic and hindbrain pathways and
demonstrated the importance of these
neural circuits in the regulation of energy
expenditure and brown adipose tissue
(BAT) activity (Figure 1).Empirical experiments using physical
lesions of specific hypothalamic nuclei
and, more recently, genetic and optoge-
netic studies have shown the importance
of neurons within the ARH, the ventrome-
dial nucleus (VMH), the dorsomedial
nucleus (DMH), the paraventricular
nucleus (PVH), and the lateral hypotha-
lamic area (LHA) in the regulation of
feeding and body weight. Lowell and
colleagues used the cre-loxP approach
to specifically delete GABAergic neuro-
transmission in rat insulin promoter
(RIP)-expressing neurons; this neuronal
population is distinct from the POMC
and AgRP neurons and is present in the
ARH, VMH, and DMH (Kong et al., 2012).
Mice lacking synaptic release of GABA
from RIP-containing neurons (Rip-Cre;
Vgatflox/flox mice) display higher body
weights and a marked increase in fat
mass. The mutant mice also show a
greater sensitivity to weight gain on a
high-fat diet (HFD). However, the elevated
body weight in chow and HFD-fed mice
could not be explained by changes in
food intake or locomotor activity, but
Kong et al. found a marked decrease in
oxygen consumption and altered BAT
thermogenesis, revealed by reduced in-terscapular temperature and UCP1 ex-
pression, which may be partially respon-
sible for the reduced energy expenditure
observed in mice lacking GABA neuro-
transmission in RIP neurons. In contrast,
blockade of glutamatergic release from
RIP-expressing neurons did not affect
energy balance, indicating that GABA is
the major neurotransmitter involved in
this process.
One of the most important functions of
RIP neurons is to mediate leptin’s effect
on energy balance (Covey et al., 2006).
Kong et al. (2012) show that the ability of
leptin to reduce body weight requires
GABA release from RIP-containing neu-
rons. In the absence of GABA neurotrans-
mission, leptin does not reduce body
weight, likely due to an inability to
increase energy expenditure and BAT
activity. RIP neurons are primarily present
in the ARH, VMH, and DMH, and each of
these nuclei is a direct target for leptin
(Patterson et al., 2011). To define the
RIP neurons responsible for the bulk of
leptin action, Kong et al. (2012) examined
leptin-induced pSTAT3, a marker of leptin
receptor activation, in Rip-Cre; lox-GFP
mice and found cells coexpressing
pSTAT3 and Cre mainly in the ARH andNovember 7, 2012 ª2012 Elsevier Inc. 557
